The portfolio features PAT devices that allow for real-time monitoring, control, and analysis of processes. These tools are designed to enhance efficiency and accuracy in various applications.
RGEN has released solid results for the fourth quarter and has provided forecasts for 2025.
Repligen Corporation (NASDAQ:RGEN) held its Q4 2024 Earnings Call on February 20, 2025, at 8:30 AM ET. The call featured company representatives, including Sondra Newman, Olivier Loeillot, and Jason Garland, as well as various conference call participants from different financial institutions. The operator welcomed everyone to the call.
Repligen (RGEN 7.92%), a company that specializes in bioprocessing technology, shared its fourth-quarter earnings on February 20. Their adjusted earnings per share (EPS) was $0.44, which was higher than the analysts' expected $0.41, although it was lower compared to the same period last year.
A webcast and conference call will take place on Thursday, February 20, 2025, at 8:30 a.m. ET.
Repligen (RGEN) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to a further increase in the stock price in the short term.
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, taking place from January 13 to 16 in San Francisco. Olivier Loeillot, the President and CEO, will give a presentation about the company on Tuesday, January 14 at 1:30 p.m. PT.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in life sciences and bioprocessing technology, has announced the launch of its CTech™ SoloVPE® PLUS System. This system is the latest and most advanced UV-based Variable Pathlength Technology available for biopharmaceutical manufacturers.
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has released its 2023 Corporate Sustainability Report. Titled “Advancing Impacts,” the report highlights the company's efforts in sustainability across six main areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways. It also includes detailed information that aligns with four major reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).
Repligen (RGEN) shared its earnings report 30 days ago. What can we expect for the stock moving forward?